platinum-based chemotherapy

February 26, 2020February 27, 2020

Zejula as First-line Treatment for Advanced Ovarian Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has accepted GSK‘s request to extend approval for Zejula (niraparib) to include as a first-line maintenance therapy for women with newly diagnosed and ... Read more

January 20, 2020January 20, 2020

Add-on NAMPT Inhibitor Prolonged Survival in Ovarian Cancer Mouse Model, Study Found

News

Using standard platinum-based chemotherapy is often associated with the formation of unfavorable treatment-resistant cancer stem cells, which may ultimately contribute to cancer progression — but inhibiting an enzyme called NAMPT ... Read more

January 8, 2020

Second Surgery for Recurrent Ovarian Cancer Does Not Improve Survival, Phase 3 Trial Shows

News

A second surgery followed by chemotherapy is no better than chemotherapy alone at extending the lives of women with platinum-sensitive ovarian cancer who experienced disease recurrence after a first surgery. ... Read more

October 28, 2019October 30, 2019

Trabectedin, Bevacizumab, Platinum Chemotherapy Combo May Work, But Safety a Concern, Study Finds

News

Women with ovarian cancer who are partially sensitive to platinum-based chemotherapy may benefit from a new combination therapy — but safety concerns need to be addressed first, a study suggests. ... Read more

September 27, 2019

Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows

News

Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of ... Read more

October 10, 2018

CT45 Protein Predicts Longer Survival Times in Advanced-stage Ovarian Cancer, Study Reports

News

A protein called CT45 predicts which ovarian cancer patients will respond to platinum-based chemotherapy and is associated with extended survival in these patients, being a new prognostic marker for ovarian ... Read more

June 20, 2018

Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer

News

Women in England and Wales with recurrent, platinum-sensitive ovarian cancer can now access Zejula (niraparib) through the Cancer Drugs Fund (CDF) after a recommendation by the U.K.’s National Institute for Health and Care ... Read more

April 30, 2018

Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial

News

Zejula (niraparib) showed an ability to treat people with recurrent and heavily treated ovarian cancer, particularly those with mutations in DNA repairing genes, results of a Phase 2 trial show. Tesaro’s ... Read more

November 8, 2017

Study Examines Chemotherapy Options for Partially Platinum-Sensitive OC Patients

News

Platinum-based chemotherapy (PBC) should be not be delayed in favor of non-platinum-based chemotherapy (NPBC) in patients with partially platinum-sensitive ovarian cancer, a new study shows. The study, “Randomized Controlled Trial ... Read more

August 19, 2017

Lynparza’s New Tablet Formulation Receives FDA Approval For Ovarian Cancer

News

A new formulation of Lynparza (olaparib) tablets received FDA approval to prevent disease progression and relapse in ovarian cancer patients. The new tablets allow patients previously taking the drug in capsule ... Read more